Phibro Q3 Sales Up 10% as MFA Acquisition Pays Off; VERRATAIN Sustainability Platform Launches

Q3 fiscal 2026 net sales at Phibro Animal Health (NASDAQ: PAHC) came in at $383.5 million, up 10%, with raised full-year guidance and a new sustainability platform called VERRATAIN launched through a partnership with VAXA Technologies. The print confirms the medicated feed additive portfolio Phibro acquired in October 2024 is delivering. The platform launch positions the company at a layer of the pet food and animal protein supply chain that almost no operator currently competes for.

Phibro Q3 sales up 10%, VERRATAIN sustainability platform launches

Q3 fiscal 2026 net sales at Phibro were $383.5 million, an increase of $35.7 million or 10% year over year. Net income was $24.0 million, up 15%. Adjusted net income grew 19% to $31.2 million, with adjusted diluted EPS of $0.76, up from $0.64 a year ago. Adjusted EBITDA was $60.8 million.

The Animal Health segment drove the quarter. Segment net sales rose to $291.2 million, up $32.8 million or 13%. Medicated feed additive (MFA) and other sales were up $24.1 million, or 13%, reflecting $18.9 million in incremental revenue from the MFA portfolio acquired in October 2024 and stronger demand for legacy products in North America.

Full-year fiscal 2026 guidance was raised to net sales of $1.46 billion to $1.50 billion and adjusted EBITDA of $247 million to $255 million.

In a separate announcement the same day, Phibro launched the Sustainable Solutions Platform (SSP) and introduced VERRATAIN Verified Sustainability Solutions through a strategic partnership with VAXA Technologies.

The platform is positioned to help animal protein, dairy, and pet food producers address greenhouse gas emissions through science-based solutions that integrate into existing feed and production systems.

Why pet food sustainability is becoming an ingredient-supply problem

Two stories in one print, and both matter to operators.

1. The MFA acquisition is producing. When Phibro acquired the MFA portfolio in October 2024, the bear case was that it was a cyclical livestock-feed asset that wouldn't compound. Q3 shows $18.9 million of incremental revenue and a 13% segment growth rate, with management raising guidance off the back of it. The integration is working. For pet-side operators, this matters because MFA economics often subsidize the R&D and regulatory infrastructure animal health companies use across species. A profitable MFA business funds the next companion animal launch.

2. VERRATAIN positions Phibro at the sustainability supply layer. Pet food has been forced into the sustainability conversation by retailer scorecards (Walmart's Project Gigaton) and the next wave of EU regulatory disclosure flowing into US private-label pet food production. The category response has been mostly marketing — recyclable packaging claims, regenerative-agriculture sourcing pilots, "carbon-neutral" certifications. VERRATAIN sits at a different layer: feed and production additives that measurably reduce greenhouse gas emissions per unit of output.

3. Sustainability claims are about to become an ingredient-supply problem, not a marketing problem. As scope-3 emissions disclosure spreads through the pet food supply chain, brands will need verified upstream inputs, not press releases. Operators who have built brand around "sustainability" without verified upstream inputs are exposed. Phibro is one of the first animal health companies positioning at this layer. The vendor list pet food contract manufacturers and ingredient buyers evaluate (Cargill, ADM, Royal DSM, Kemin) just got longer.

4. The category opportunity is structurally larger than the press release suggests. The global animal feed additives market is projected to grow from roughly $50 billion in 2025 to $82 billion by 2033 at a ~6% CAGR. Sustainable animal feed inside that TAM is the fastest-growing slice — $20 billion in 2025, projected to $149 billion by 2035 at a 23% CAGR. Even single-digit penetration of verified sustainability solutions across protein, dairy, and pet food is a multi-billion-dollar opportunity, and the regulatory clock is favorable.

5. Phibro is now a structurally different company. The Q3 numbers and the VERRATAIN launch read as one coherent thesis. Phibro is using its livestock feed-additive distribution and regulatory infrastructure to extend into a higher-margin services and verification business. That changes how the equity gets owned, and it changes who Phibro competes with — Cargill and Kemin instead of just Elanco's livestock arm.

What VERRATAIN customer signings will reveal

Organic versus acquired MFA contribution: Whether the next print shows continued double-digit segment growth, and what the mix looks like once the October 2024 acquisition laps. The market will pay for organic compounding and discount one-time acquisition lift.

VERRATAIN customer signings: The platform's value will be made or unmade by which Big Pet Food and Big Protein producers sign on. A multi-year supply agreement for verified sustainability inputs is a meaningful proof point. Absence of signings within twelve months is the bear case.

Competitor response: Cargill, ADM, DSM-Firmenich, and Kemin all overlap with this positioning. Kemin's recent acquisition of Bactana for intestinal health and fermentation technology is in the same direction. Watch for a competing platform launch.

Pet food contract manufacturer adoption: If a major US private-label pet food CM or co-manufacturer announces VERRATAIN-verified inputs, the platform has scaled into the pet-side supply chain.

Margin trajectory: The services-and-verification business should carry materially higher margin than the underlying MFA portfolio. Watch for adjusted EBITDA margin lift in fiscal 2027 guidance as VERRATAIN revenue mixes in.

Source: Phibro Animal Health Q3 FY26 release via Business Wire